Page 108 - Read Online

Page 6 of 7 Di Nora et al. Vessel Plus 2022;6:46 https://dx.doi.org/10.20517/2574-1209.2021.126

Copyright
© The Author(s) 2022.

REFERENCES
1. Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging
findings. Eur J Prev Cardiol 2020;27:1806-15. DOI PubMed
2. Nienhuis HL, Bijzet J, Hazenberg BP. The prevalence and management of systemic amyloidosis in western countries. Kidney Dis
(Basel) 2016;2:10-9. DOI PubMed PMC
3. Simões MV, Fernandes F, Marcondes-braga FG, et al. Posicionamento sobre diagnóstico e tratamento da amiloidose cardíaca - 2021.
Arquivos Brasileiros de Cardiologia 2021;117:561-98. DOI
4. Debonnaire P, Claeys M, De Smet M, et al. Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de
novo cardiac amyloidosis and their multidisciplinary implications. Acta Cardiol ;2021:1-14. DOI PubMed
5. Oubari S, Naser E, Papathanasiou M, et al. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients
with AL amyloidosis and cardiac involvement. Eur J Haematol 2021;107:449-57. DOI PubMed
6. Elsayed M, Usher S, Habib MH, et al. Current updates on the management of AL amyloidosis. J Hematol 2020;10:147-61. DOI
PubMed PMC
7. Biliński J, Biernacka EK, Januszewicz A. Cardiac amyloidosis secondary to multiple myeloma: successful sequential cardiac and
autologous stem cell transplantations with excellent outcome. Eur Heart J 2021;42:3803. DOI PubMed
8. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain
amyloidosis. Leukemia 2012;26:2317-25. DOI PubMed
9. Tahir UA, Doros G, Kim JS, et al. Predictors of mortality in light chain cardiac amyloidosis with heart failure. Sci Rep 2019;9:8552.
DOI PubMed PMC
10. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Hematology Am Soc Hematol Educ Program
2020;2020:363-71. DOI PubMed PMC
11. Frustaci A, Galea N, Verardo R, et al. Kappa-light chain amyloid overlapping hypertrophic cardiomyopathy with myocardial
noncompaction. Circ Cardiovasc Imaging 2020;13:e010379. DOI PubMed
12. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an
early mortality risk score. Mayo Clin Proc 2011;86:12-8. DOI PubMed PMC
13. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and
management of cardiac amyloidosis. Circulation 2017;135:1357-77. DOI PubMed PMC
14. Hall R, Hawkins PN. Cardiac transplantation for AL amyloidosis. BMJ 1994;309:1135-7. DOI PubMed PMC
15. Vaidya GN, Patel JK, Kittleson M, et al. Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era.
Clin Transplant 2021;35:e14308. DOI PubMed
16. Hosenpud JD, Uretsky BF, Griffith BP, et al. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing
heart transplantation: results of a multicentre survey. J Heart Transplant 1990;9:346-50. DOI
17. Conner R, Hosenpud JD, Norman DJ, et al. Heart transplantation for cardiac amyloidosis: successful one-year outcome despite
recurrence of the disease. J Heart Transplant 1988;7:165-7 PubMed
18. Kpodonu J, Massad MG, Caines A, Geha AS. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart
Lung Transplant 2005;24:1763-5. DOI PubMed
19. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL
amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93. DOI PubMed
20. Gillmore JD, Goodman HJ, Lachmann HJ, et al. Sequential heart and autologous stem cell transplantation for systemic AL
amyloidosis. Blood 2006;107:1227-9. DOI PubMed
21. Kristen AV, Sack FU, Schonland SO, et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe
cardiac light-chain amyloidosis. Eur J Heart Fail 2009;11:1014-20. DOI PubMed
22. Okamoto S, Zhao Y, Lindqvist P, et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin
amyloidosis (ATTR) patients. Amyloid 2011;18:200-5. DOI PubMed
23. Sickels A, Shah KB, Ruch B, et al. Combined heart-liver and domino liver transplantation in familial amyloidosis. Am Surg
2021:31348211023427. DOI PubMed
24. Rosenbaum AN, AbouEzzeddine OF, Grogan M, et al. Outcomes after cardiac transplant for wild type transthyretin amyloidosis.
Transplantation 2018;102:1909-13. DOI PubMed
25. Mehra MR, Canter CE, Hannan MM, et al; International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases;
Pediatric and Heart Failure and Transplantation Councils. The 2016 international society for heart lung transplantation listing criteria
for heart transplantation: a 10-year update. J Heart Lung Transplant 2016;35:1-23. DOI PubMed
26. Roig E, Almenar L, Gonzalez-Vilchez F, et al. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish
registry for heart transplantation. Am J Transplant 2009;9:1414-9. DOI PubMed
27. Lacy MQ, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid
cardiomyopathy. J Heart Lung Transplant 2008;27:823-9. DOI PubMed